DNase-Armored CAR T Platform
Multiple Solid Cancers
ResearchEarly exploratory program (with Volition)
Key Facts
Indication
Multiple Solid Cancers
Phase
Research
Status
Early exploratory program (with Volition)
Company
About Xenetic Biosciences
Xenetic Biosciences is a publicly-traded biopharma company developing adjunctive cancer therapies based on its DNase I platform, which targets neutrophil extracellular traps (NETs) to overcome resistance to standard treatments. The company is strategically positioned in the high-value oncology space, with a focus on pancreatic cancer and other solid tumors, and is backed by a team with significant industry experience. Its strategy involves advancing its lead candidate into clinical trials while leveraging key partnerships with research institutions and manufacturing organizations.
View full company profile